Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.569 +0.049 (+3.25%)
Streaming Delayed Price Updated: 9:50 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗
Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials. 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
Via Stocktwits
News headline image
Expert Ratings For Caribou Biosciences ↗
 
Via Benzinga
News headline image
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Evaluating Caribou Biosciences: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss ↗
Caribou Biosciences reports Q2 2025 earnings with revenue beating estimates at $2.67M but a wider EPS loss of -$0.58. Clinical updates expected in H2 2025. 
Via Chartmill
News headline image
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences ↗
 
Via Benzinga
News headline image
Expert Ratings For Caribou Biosciences ↗
 
Via Benzinga
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Attention Biotech Investors - Stocks To Watch ↗
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
News headline image
3 Underappreciated Stocks That Could 10x in 10 Years ↗
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line. 
Via InvestorPlace
News headline image
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024 ↗
CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points ↗
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday. 
Via Benzinga
Topics Economy Stocks
News headline image
Gold Down Over 1%; ClearOne Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Caribou Biosciences Stock Is Crashing Today ↗
Investors didn't like the clinical-stage biotech's Q4 update for one key reason. 
Via The Motley Fool
News headline image
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
News headline image
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗
Buy this stock if you're daring, but avoid it for now if you aren't. 
Via The Motley Fool
News headline image
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare ↗
It's less scary to take on risky investments when the market is rising. 
Via The Motley Fool
News headline image
3 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These companies are still in the early innings of their growth potential. 
Via The Motley Fool
News headline image
3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.